Compare
Matinas BioPharma Holdings, Inc. vs Cannapharmarx, Inc. vs CV Sciences, Inc. vs Serina Therapeutics, Inc.
| Latest fiscal year | Matinas BioPharma Holdings, Inc. MTNB | Cannapharmarx, Inc. CPMD | CV Sciences, Inc. CVSI | Serina Therapeutics, Inc. SER |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.36M | $13.79M | $130.0K |
| Revenue growth (YoY) | n/a | +66.1% | -12.2% | +132.1% |
| Gross margin | n/a | -153.1% | 49.0% | n/a |
| Operating margin | n/a | -245.8% | -3.4% | n/m |
| Net margin | n/a | -817.2% | -6.9% | n/m |
| Net income | -$10.35M | -$11.13M | -$958.0K | -$19.18M |
| EPS (Diluted) | -$2.00 | -$0.02 | -$0.01 | -$1.91 |
| Operating cash flow | -$7.01M | -$789.1K | -$407.0K | -$17.95M |
| Free cash flow | n/a | -$794.6K | -$516.0K | -$18.01M |
| Cash & equivalents | $4.00M | $1.8K | n/a | $3.06M |
| Total assets | $7.21M | $7.02M | $6.96M | $6.95M |
| Total liabilities | $2.38M | $37.17M | $5.49M | $6.99M |
| Shareholders' equity | $4.83M | -$30.15M | $1.47M | -$37.0K |
| Return on year-end equity | -214.2% | n/a | -65.3% | n/a |
| Shares outstanding | 6.41M | 662.50M | 184.26M | 10.77M |
Revenue, most recent five fiscal years
| Fiscal year | Matinas BioPharma Holdings, Inc. | Cannapharmarx, Inc. | CV Sciences, Inc. | Serina Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.10M Ended 2023-12-31 | $1.36M Ended 2025-12-31 | $13.79M Ended 2025-12-31 | $130.0K Ended 2025-12-31 |
| 1 year earlier | $3.19M Ended 2022-12-31 | $820.1K Ended 2024-12-31 | $15.71M Ended 2024-12-31 | $56.0K Ended 2024-12-31 |
| 2 years earlier | $33.0K Ended 2021-12-31 | $0 Ended 2023-12-31 | $16.00M Ended 2023-12-31 | $3.15M Ended 2023-12-31 |
| 3 years earlier | $158.3K Ended 2020-12-31 | $0 Ended 2022-12-31 | $16.20M Ended 2022-12-31 | $34.0K Ended 2022-12-31 |
| 4 years earlier | $89.8K Ended 2019-12-31 | $0 Ended 2021-12-31 | $20.05M Ended 2021-12-31 | $144.0K Ended 2021-12-31 |